About this trial
Stroke is a leading cause of death and disability worldwide. A major complication of stroke is spasticity, marked by increased muscle tone and impaired movement. It affects majority stroke patients and complicates rehabilitation, affecting the upper limb function of survivors.
While traditional treatments like oral medications and botulinum toxin injections offer some relief, they have notable limitations, causing the need for novel, non-invasive approaches. Extracorporeal shock wave therapy (ESWT), which uses acoustic waves for regeneration and neuromodulation, has shown promise in reducing spasticity with minimal side effects, though its precise mechanisms and ideal protocols need further study. Current evidence supports ESWT's efficacy and safety, often matching established treatments, but gaps remain regarding standardized application and long-term functional outcomes, highlighting the need for more robust research.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosed as 1st stroke incidence 6 months back
Both male and female
Age 25 to 65 years
the ability to follow verbal instructions
Disqualifiers
Recurrent stroke.
Severe contractures or deformities of upper extremity.
Chronic pain affecting upper extremity function.
malignant tumor, pacemakers, infection
Trial design
Parallel
Treatments tested in this trial
ESWT
Other interventionTarget muscles: biceps brachii, flexor carpi radialis, pronator teres, wrist and finger flexors. Protocol: 2000 shocks per muscle per session, energy flux density 0.03 mJ/mm², frequency 8 Hz, pressure \~0.2 MPa (2 bars).(1)
Stretching
Other interventionSustained stretches held for 10 seconds, 3-5 repetitions per muscle group
Mobility
Other interventionActive and passive range of motion (ROM) exercises, 10-15 reps
Strengthening
Other interventionIsometric/ Isotonic exercises for antagonist muscles, 3 sets of 10-15 reps
Functional training
Other interventionTask-oriented activities ADLs. Eg: grasping, reaching, manipulation, 20-30 minutes per session
Treatment groups
Trial outcomes
Primary outcomes
Upper limb function test
The upper limb function will be evaluated using the Neofect Smart Board test. The test will involve three different kinematic assessment programs: free exploration, point-to-point reaching, and circle-drawing.Data will be recorded as time taken to complete the evaluation (s) then the average of three tasks will serve to denote the upperlimb function. Each assessment program has a time limit of 60 s. (2)
Secondary outcomes
Electrical activation of muscle
Muscle activity will be objectively assessed using using the BTS, Electromyography (EMG) system to measure amplitude of root mean square (RMS) (µV).(3) RMS reflects the overall level at rest and during movement.The subject will be asked to be seated comfortably on a chair with his/her arm rested on a table, elbow extension at 110°-120°, and the wrist placed in the neutral position. The subject will be requested four motion patterns spherical grasp, hand opening, tripod pinch , and hook grip. Each movement will be performed 3 times in pair, for accuracy. During this process six EMG sensors will placed on the six muscles: flexor digitorum superficialis (FDS), flexor digitorum Profundus (FDP), medial head of extensor digitorum (EDM), lateral head of extensor digitorum (EDL), extensor pollicis longus (EPL), and extensor carpi radialis longus (ECR) muscle on the tested side.(3)
Muscles force generating capacity
Muscle's highest force-generating capacity during voluntary effort will be recorded with maximum voluntary contraction (MVC) (expressed as %).(3). The subject will be asked to follow the same EMG procedure denoted for recording the overall electrical activity of the muscle. Except in each pair of movement, one movement will be performed at maximum voluntary contraction (MVC) and the other one at comfortable force.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.